Pioneering MRI Tech with New Agent

So the plan is first we just go in, we enter into the current workflow, we replace those black and white gadolinium images with our black and white images that are better. How do we do that? We get clearance of the software that enables that scan at the scanner and approval of the contrast agent, which is an iron oxide. And we sell that contrast agent and we sell it and we make a lot of money off selling that contrast agent because we're going to need a lot of money to reinvest into those other applications, like for Alzheimer's disease, that are going to take millions and millions and millions of more dollars to develop paid per clip application so that you got enough data to where we know what Alzheimer's looks like throughout the whole process so that we got enough data to know what a stroke looks like. It's going to take so much data, it's going to take so many millions of dollars. So our plan is first just get the black and white images out there, sell the ink. Right, which is the contrast agent. Sell the contrast agent and fuel these other innovations.